Strengthening tuberculosis control overseas: who benefits?

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Hoa Thi Minh NguyenKamalini M Lokuge

Abstract

Although tuberculosis is a major cause of morbidity and mortality worldwide, available funding falls far short of that required for effective control. Economic and spillover consequences of investments in the treatment of tuberculosis are unclear, particularly when steep gradients in the disease and response are linked by population movements, such as that between Papua New Guinea (PNG) and the Australian cross-border region. To undertake an economic evaluation of Australian support for the expansion of basic Directly Observed Treatment, Short Course in the PNG border area of the South Fly from the current level of 14% coverage. Both cost-utility analysis and cost-benefit analysis were applied to models that allow for population movement across regions with different characteristics of tuberculosis burden, transmission, and access to treatment. Cost-benefit data were drawn primarily from estimates published by the World Health Organization, and disease transmission data were drawn from a previously published model. Investing $16 million to increase basic Directly Observed Treatment, Short Course coverage in the South Fly generates a net present value of roughly $74 million for Australia (discounted 2005 dollars). The cost per d...Continue Reading

References

Dec 1, 1992·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·L Bonvin, J P Zellweger
Mar 15, 1986·British Medical Journal·N Horsfield, L P Ormerod
Apr 20, 1995·The New England Journal of Medicine·M T McKennaI Onorato
Aug 1, 1993·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·L A Gaudette, E Ellis
Oct 16, 1996·JAMA : the Journal of the American Medical Association·M C WeinsteinL B Russell
Dec 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N J BinkinK G Castro
Jun 15, 1997·American Journal of Epidemiology·M A Sanchez, S M Blower
Jun 8, 2000·Medical Care·T O Tengs, A Wallace
Jul 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F G CobelensM E Mensen
Jul 24, 2004·BMJ : British Medical Journal·Michael D Rawlins, Anthony J Culyer
Sep 15, 2004·Journal of Epidemiology and Community Health·Timothy F Brewer, S Jody Heymann
Sep 16, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Hans-Georg EichlerBengt Jönsson
Mar 2, 2005·International Journal of Technology Assessment in Health Care·Cynthia P IglesiasUNKNOWN NEVALAT Project Group
Apr 7, 2005·Journal of Health Economics·Richard D Smith
Sep 9, 2005·The New England Journal of Medicine·Kevin SchwartzmanDick Menzies
Sep 27, 2005·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Richard FrothinghamCarol Dukes Hamilton
Nov 12, 2005·BMJ : British Medical Journal·Rob BaltussenChristopher Dye
Nov 24, 2005·JAMA : the Journal of the American Medical Association·David A HenryAnthony Harris
Dec 6, 2005·Social Science & Medicine·Amiram Gafni, Stephen Birch
Jul 20, 2007·Bulletin of the World Health Organization·Katherine FloydChristopher Dye
Jan 28, 2009·BMJ : British Medical Journal·Adrian Towse
Mar 31, 2009·Journal of Health Economics·Jose Luis Pinto-PradesRaul Brey
Sep 10, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Ana BobinacWerner B F Brouwer

❮ Previous
Next ❯

Citations

Mar 25, 2016·Infectious Diseases of Poverty·Rachel M Anderson de CuevasLuis E Cuevas
Apr 29, 2020·International Journal of Technology Assessment in Health Care·Xue FengDaniel A Ollendorf
Apr 16, 2019·Communicable Diseases Intelligence·UNKNOWN The National Tuberculosis Advisory Committee for the Communicable Diseases Network Australia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Papua and New Guinea Medical Journal
M H LevyV Krause
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
G L Stoddart
© 2021 Meta ULC. All rights reserved